# Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults

> **NCT06821126** · PHASE1,PHASE2 · RECRUITING · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 238 (estimated)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** LVT-001
- **BIOLOGICAL:** Cormirnaty

## Key facts

- **NCT ID:** NCT06821126
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-09
- **Primary completion:** 2026-10
- **Final completion:** 2028-03
- **Target enrollment:** 238 (ESTIMATED)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06821126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06821126, "Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06821126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*